TG Therapeutics (TGTX)
(Delayed Data from NSDQ)
$28.40 USD
-0.32 (-1.11%)
Updated Aug 5, 2025 03:59 PM ET
After-Market: $28.39 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, TG Therapeutics, Inc. has a market cap of $4.56B, which represents its share price of $28.72 multiplied by its outstanding shares number of 158.76M. As a mid-cap company, TGTX's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
TGTX 28.40 -0.32(-1.11%)
Will TGTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TGTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TGTX
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line
Company News for Aug 5, 2025
TGTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
TG Therapeutics (TGTX) Misses Q2 Earnings Estimates
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release
Other News for TGTX
TG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ...
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results
TGTX Stock Drops Over 14% Following Latest Market Movements
Tesla grants Musk big payout, Wayfair reports Q2 beat: Morning Buzz
Q2 2025 TG Therapeutics Inc Earnings Call Transcript